Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the gastrointestinal tract

• Published in: Virchows Archiv : an international journal of pathology Vol. 463; no. 6; pp. 811 - 818
• Main Authors: D’Souza, Amber M., Phillips, Gary S., Pohar, Kamal S., Zynger, Debra L.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2013; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Bladder cancer; Carcinoma, Transitional Cell - mortality; Carcinoma, Transitional Cell - secondary; Female; Gastrointestinal Neoplasms - mortality; Gastrointestinal Neoplasms - secondary; Gastrointestinal tract; Humans; Kaplan-Meier Estimate; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Original Article; Pathology; Proportional Hazards Models; Retrospective Studies; Survival; Urinary Bladder Neoplasms - mortality; Urinary Bladder Neoplasms - pathology; Young Adult; Bladder; Urothelial; Gastrointestinal; Staging; Survival
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s00428-013-1479-0

Involvement of the gastrointestinal (GI) tract by bladder cancer is rare and documented in only a few case reports with no prognostic information available. The aim of this study was to clinicopathologically characterize patients with pathologically proven bladder cancer in the GI tract. We reviewed pathology reports from cystectomy patients at our institution from 2006 to 2011, identifying those with GI involvement at or after cystectomy. Overall survival (OS) was analyzed using Kaplan–Meier curves and Cox proportional hazard regression models. Twelve patients had surgical pathology specimens with GI involvement (anus, rectum, colon, and small bowel) at ( n  = 11) or within 4 months ( n  = 1) of cystectomy. These patients were noted to be pathologically staged inconsistently. GI involvement was a negative predictor of survival, with a 1.5-year OS of 25 versus 62 % without GI involvement ( P  < 0.001), similar to our pT4 patients (OS 26 %). In node-negative patients, there was a significantly worse 1.5-year OS with GI involvement compared to those without tumor in the GI tract ( P  = 0.005). We provide the first case series of patients with bladder cancer in the GI tract. GI involvement is a strong negative predictor of survival and behaves comparable to pT4 patients. However, we recommend that pathologists adhere to the current pT staging guidelines, in which GI involvement is not a criterion, until further research is conducted illustrating if and how it should be incorporated.